

News Releases

All Years

Search

Go

[Advanced Search](#)

AUG 8, 2022

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

JUN 30, 2022

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance

MAY 19, 2022

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

MAY 12, 2022

Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

MAY 9, 2022

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

MAR 24, 2022

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

FEB 28, 2022

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

FEB 22, 2022

Inhibrx Announces Amended Loan Agreement with Oxford

JAN 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

DEC 1, 2021

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

Show per
page

« [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) »



<https://inhibrx.investorroom.com/news-releases?l=10&o=40>